Woodcock Ian R, Menezes Manoj P, Coleman Lee, Yaplito-Lee Joy, Peters Heidi, White Susan M, Stapleton Rachel, Phelan Dean G, Chong Belinda, Lunke Sebastian, Stark Zornitza, Pitt James, Ryan Monique M, Robertson Colin, Yiu Eppie M
From the Department of Neurology, Royal Children's Hospital, Melbourne, Australia; Neurosciences Research, Murdoch Childrens Research Institute, Melbourne, Australia.
T.Y. Nelson Department of Neurology and Neurosurgery, The Institute for Neuroscience and Muscle Research, The Children's Hospital at Westmead, Westmead, Australia; Paediatrics and Child Health, University of Sydney, Camperdown, Australia.
Semin Pediatr Neurol. 2018 Jul;26:2-9. doi: 10.1016/j.spen.2017.03.001. Epub 2017 Apr 5.
Brown-Vialetto-van Laere syndrome is characterized by a progressive sensorimotor neuropathy, optic atrophy, hearing loss, bulbar dysfunction, and respiratory insufficiency. Mutations in SLC52A2 and SLC52A3, encoding riboflavin transporters RFVT2 and RFVT3, respectively, are the genetic basis of this disorder, often referred to as riboflavin transporter deficiency types 2 and 3, respectively. We present cases of both types of riboflavin transporter deficiency, highlighting the distinguishing clinical features of a rapidly progressive motor or sensorimotor axonal neuropathy, optic atrophy, sensorineural hearing loss, and bulbar dysfunction. One child presented with isolated central apnea and hypoventilation, not previously described in genetically confirmed Brown-Vialetto-van Laere, later complicated by diaphragmatic paralysis secondary to phrenic nerve palsy. Magnetic resonance imaging showed T2 hyperintensity in the dorsal spinal cord in 2 children, as well as previously unreported cervical nerve root enlargement and cauda equina ventral nerve root enhancement in 1 child. Novel homozygous mutations were identified in each gene-a NM_024531.4(SLC52A2):c.505C > T, NP_078807.1(SLC52A2):p.(Arg169Cys) variant in SLC52A2 and NM_033409.3(SLC52A3):c.1316G > A, NP_212134.3(SLC52A3):p.(Gly439Asp) variant in SLC52A3. Both treated children showed improvement on high-dose riboflavin supplementation, highlighting the importance of early recognition of this treatable clinical entity.
布朗 - 维阿莱托 - 范莱尔综合征的特征为进行性感觉运动神经病、视神经萎缩、听力丧失、延髓功能障碍和呼吸功能不全。分别编码核黄素转运蛋白RFVT2和RFVT3的SLC52A2和SLC52A3基因发生突变是该疾病的遗传基础,该疾病通常分别被称为核黄素转运蛋白缺乏症2型和3型。我们报告了这两种类型的核黄素转运蛋白缺乏症病例,突出了快速进展的运动或感觉运动轴索性神经病、视神经萎缩、感音神经性听力丧失和延髓功能障碍的显著临床特征。一名儿童表现为孤立的中枢性呼吸暂停和通气不足,这在基因确诊的布朗 - 维阿莱托 - 范莱尔综合征中未曾描述过,后来因膈神经麻痹继发膈肌麻痹而病情复杂化。磁共振成像显示2名儿童的脊髓背侧T2高信号,以及1名儿童先前未报告的颈神经根增粗和马尾腹侧神经根强化。在每个基因中都鉴定出了新的纯合突变——SLC52A2基因中的NM_024531.4(SLC52A2):c.505C > T、NP_078807.1(SLC52A2):p.(Arg169Cys)变异以及SLC52A3基因中的NM_033409.3(SLC52A3):c.1316G > A、NP_212134.3(SLC52A3):p.(Gly439Asp)变异。两名接受治疗的儿童在补充高剂量核黄素后均有改善,突出了早期识别这种可治疗临床病症的重要性。